The clinical-grade, laboratory-developed test for polygenic risk score for coronary artery disease, breast cancer, prostate cancer, Type 2 Diabetes, and Alzheimer’s disease is now available for purchase direct from Allelica.
| The clinical-grade, laboratory-developed test for polygenic risk score for coronary artery disease, breast cancer, prostate cancer, Type 2 Diabetes, and Alzheimer’s disease is now available for purchase direct from Allelica NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Allelica, a leading genomics software company that provides digital tools for the development, validation and calculation of ancestry-specific polygenic risk scores (PRSs), announced that PRS analysis is now available as a laboratory-developed test (LDT) for healthcare providers looking to improve health outcomes. The test is made possible through a partnership with Clinical Enterprise Inc., a CLIA-certified, CAP-accredited laboratory located in Framingham, Mass.
Brigham and Women’s Hospital is among the first healthcare facilities to make the test available through its Preventive Genomics Clinic, where PRS is being used, along with comprehensive whole-genome sequencing, to provide patients with personal disease risk factors. “Polygenic risk scores are an exciting new tool to identify individuals at increased risk for common complex disorders like heart disease, diabetes, and common forms of cancer,” said Robert Green, a medical geneticist and professor of medicine at Brigham and Women’s Hospital, Ariadne Labs and Harvard Medical School, who is a scientific advisor to the company. “Identifying those at highest risk means that surveillance and intervention can be focused earlier and have a greater impact, moving us closer to proactive and preventive health care, rather than reactive sick care.” Allelica’s new, ancestry-specific PRS tests are available as a physician-ordered test and set new standards for accessibility, accuracy, and cost. The tests use a patient’s saliva as a DNA sample for genotyping analysis carried out by Clinical Enterprise. The analysis leverages genome-wide microarray technology that takes into account hundreds of thousands of genetic variants and offers significant cost savings compared to whole-genome sequencing. The output of the microarray analysis is input into the Allelica platform, which applies proprietary algorithms to calculate an ancestry-specific PRS and generate clinical-grade reports. Allelica PRS algorithms have been developed and validated in multiple prospective datasets that include individuals of all continental ancestries. The reports, which are also available as a white-label package, are delivered to providers through a secure portal or through integration with electronic medical records. Available immediately are tests for coronary artery disease, breast cancer, prostate cancer, Type 2 Diabetes, and Alzheimer’s disease. They can be ordered as standalone tests for a single PRS or as panels with multiple PRSs. Allelica plans to expand testing to include more diseases across cardiology, oncology, and women’s health. Giordano Bottà, CEO of Allelica, sees the announcement as an important milestone for genomic medicine because it integrates polygenic risk score analysis and reporting into the clinical workflow in a responsible and equitable way. “Prior PRS scores were limited by utilizing databases of largely or exclusively European ancestry. Our priority was to develop a PRS that can benefit everyone, regardless of their ancestries. By providing clinical-grade polygenic risk score testing to people of all ancestries in an accessible and scalable way, we are empowering healthcare professionals to revolutionize healthcare by applying the next generation of clinical genomics,” he said. For information on pricing and how to order the test, visit contact Allelica at info@allelica.com What is a polygenic risk score (PRS)? A PRS is a measurement of a person’s risk of disease that results from the combined effect of many DNA variants across the genome. It is calculated by combining the effect of these variants, each contributing a small increase or decrease in risk into an overall risk score. This information can be used to stratify individuals based on their risk of disease. By combining PRS with conventional risk factors, Allelica aims to make precision medicine available at scale. About Eurofins Eurofins is Testing for Life. Eurofins is the global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, and advanced material sciences, and has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing. With over 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods. Eurofins shares are listed on Euronext Paris Stock Exchange. Clinical Enterprise is part of the Eurofins network of laboratories. About Allelica Allelica is a leading genomic software company that specializes in secure and scalable solutions to implement clinical-grade polygenic risk scores (PRSs). Allelica’s technology combines world-class datasets with the most advanced algorithms to build PRSs with the highest predictive power for estimating disease risk. Allelica’s tools translate the enormous potential of genomic data into practical tools that can be used to identify individuals with a high genetic susceptibility for life-threatening diseases. Through the incorporation of genetics into disease risk assessments, Allelica is helping to build the foundations of preventive medicine by helping to identify those for whom early intervention and behavior modification could help reduce lifetime risk. To learn more, visit allelica.com.
SOURCE Allelica, Inc. |
View original content to download multimedia:
